Jun Uematsu, Hidetaka Yamamoto, Sahoko Kihira, Kae Sakai-Sugino, Yuhko Ishiyama, Misaki Chindoh, Aya Baba, Rina Kazuta, Tomomi Hasegawa, Keiko Fujimoto, Aya Funauchi, Ai Itoh, Ayumi Ookohchi, Saemi Satoh, Yurie Maeda, Mitsuo Kawano, Masato Tsurudome, Miwako Nishio, Kazuyuki Hirai, Myles O'Brien, Hiroshi Komada
Thirteen herbal medicines, Kakkonto (TJ-001), Kakkontokasenkyushin'i (TJ-002), Hangekobokuto (TJ-016), Shoseiryuto (TJ-019), Maoto (TJ-027), Bakumondoto (TJ-029), Hochuekkito (TJ-041), Goshakusan (TJ-063), Kososan (TJ-070), Chikujountanto (TJ-091), Gokoto (TJ-095), Saibokuto (TJ-096), and Ryokankyomishingeninto (TJ-119) were tested for human parainfluenza virus type 2 (hPIV-2) replication. Eight (TJ-001, TJ-002, TJ-019, TJ-029, TJ-041, TJ-063, TJ-095 and TJ-119) out of the thirteen medicines had virus growth inhibitory activity...
August 26, 2021: Drug Discoveries & Therapeutics